Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification

(2017) Aurel Perren et al.   NEUROENDOCRINOLOGY

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

(2017) Rodney J. Hicks et al.   NEUROENDOCRINOLOGY

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications

(2016) Nicola Fazio et al.   CANCER TREATMENT REVIEWS

High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours

(2016) Grace Kong et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms

(2016) J.K. Ramage et al.   NEUROENDOCRINOLOGY

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

(2016) M. Pavel et al.   NEUROENDOCRINOLOGY

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

(2016) R. Garcia-Carbonero et al.   NEUROENDOCRINOLOGY

PET/CT and Bremsstrahlung Imaging After 90Y DOTANOC Therapy for Rectal Net With Liver Metastases

(2015) Ümmühan Abdülrezzak et al.   CLINICAL NUCLEAR MEDICINE

Neoadjuvant90Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report

(2014) Jennifer Ryan et al.   ANZ JOURNAL OF SURGERY

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

(2014) G. Kong et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Clinical and Prognostic Features of Rectal Neuroendocrine Tumors

(2013) Brett Weinstock et al.   NEUROENDOCRINOLOGY

ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neuroendocrine Neoplasms

(2012) Martyn Caplin et al.   NEUROENDOCRINOLOGY

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study

(2012) D. Castellano et al.   ONCOLOGIST

The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors

(2011) Ben Lawrence et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) K. Oberg et al.   ANNALS OF ONCOLOGY

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

(2010) Martin B Niederle et al.   ENDOCRINE-RELATED CANCER

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

(2010) Daniel Hubble et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

(2010) Phillip G. Claringbold et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience

(2009) Grace Kong et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER